6 oxo vs. Novadex xt

[UrRoyalHighness]

Most of everyone that i know and on this board say that 6 OXO is better Than Gaspari's Novadex Xt.. I Picked up some mags and I got to reading and it said that Gaspari's is way way way better in doing its job than 6 OXO.. Can anyone elaberate...
Why is it that noone recommends the XT...

[Flex-Appeal]

personally i think novadex is bunk! gaspari made a straight wanna-be product! do not waste you money. there are test being doing to prove that it dosent even lower estrgen very much if at all. i took 2 bottles and didn't see any decent results at all.

[hldr1027]

What about 6OXO any luck with that, I have two bottle kicking about the house, never used it but want to try it, although all the gear I have to cycle is strong like M1T & SD so will probibely not risk it???

[bulldawg_28]

Here are some studies on 6oxo, and novedex.

The purpose of this study was to determine the effects of 6-OXO, a purported nutritional
aromatase inhibitor, in a dose dependent manner on body composition, serum hormone levels, and
clinical safety markers in resistance trained males. Sixteen males were supplemented with either
300 mg or 600 mg of 6-OXO in a double-blind manner for eight weeks. Blood and urine samples
were obtained at weeks 0, 1, 3, 8, and 11 (after a 3-week washout period). Blood samples were
analyzed for total testosterone (TT), free testosterone (FT), dihydrotestosterone (DHT),
estradiol, estriol, estrone, SHBG, leutinizing hormone (LH), follicle stimulating hormone (FSH),
growth hormone (GH), cortisol, FT/estradiol (T/E). Blood and urine were also analyzed for clinical
chemistry markers. Data were analyzed with two-way MANOVA. For all of the serum hormones,
there were no significant differences between groups (p > 0.05). Compared to baseline, free
testosterone underwent overall increases of 90% for 300 mg 6-OXO and 84% for 600 mg,
respectively (p < 0.05). DHT underwent significant overall increases (p < 0.05) of 192% and 265%
with 300 mg and 600 mg, respectively. T/E increased 53% and 67% for 300 mg and 600 mg 6-OXO,
respectively. For estrone, 300 mg produced an overall increase of 22%, whereas 600 mg caused a
52% increase (p < 0.05). Body composition did not change with supplementation (p > 0.05) and
clinical safety markers were not adversely affected with ingestion of either supplement dose (p >
0.05). While neither of the 6-OXO dosages appears to have any negative effects on clinical
chemistry markers, supplementation at a daily dosage of 300 mg and 600 mg for eight weeks did
not completely inhibit aromatase activity, yet significantly increased FT, DHT, and T/E.

And here's he Novedex (ATD) study.

Novedex XT Clinical Trial
OHIO RESEARCH GROUP
Ziegenfuss T.N., Mendel R.W., and Hofheins J.E. Safety and Efficacy of a Naturally-Occurring, Orally Administered, Aromatase Inhibitor in Healthy Men. Ohio Research Group of Exercise Science and Sports Nutrition. Wadsworth, Ohio 44281, USA. [email protected]his email address is being protected from spam bots, you need Javascript enabled to view it

Rationale: In healthy men, it is known that blocking estrogen formation stimulates the HPT axis to increase in vivo testosterone production. Recently, a new class of dietary supplements has appeared that claim to inhibit the aromatase enzyme (i.e., decrease the transformation of aromatizable androgens [androstenedione, DHEA, testosterone] into estrogens [estriol, estrone, estradiol]), thus stimulating an increase in testosterone formation.

Purpose: The purpose of this pilot study was to examine the effects of a popular aromatase inhibitor, Novedex XTÔ (NOV-XT), on selected hormonal responses (total testosterone [TT], bioavailable testosterone [BT] and estradiol [E2]), as well as serum and plasma markers of renal, hepatic, and hematological function.

Methods: Using an open-label, proof-of-concept design, five eugonadal men (mean ± superdrol age, height, weight, body fat: 31.6 ± 2.8 yr, 174.3 ± 1.8 cm, 84.3 ± 3.8 kg, 11.2 ± 3.3 %) ingested 4 capsules of NOV-XT prior to bed for 28 consecutive days. According to the manufacturer, each capsule of NOV-XT contains 60 mg of a proprietary blend of three naturally-occurring aromatase inhibitors: 6, 17-keto-etiocholeve-3-ol tetrahydropyranol, 3, 17-keto-etiochol-triene, and 3’,5,7-trihydroxy-4’-methoxyflavone (supplements were provided by an FDA-registered, pharmaceutically licensed manufacturer; confirmation by an external laboratory is pending). Blood samples obtained at baseline (prior to supplementation), and at weekly intervals thereafter for 28 days, were analyzed for TT, BT, and E2 by radioimmunometric and chemilluminetric assays. Subjects were required to maintain their normal dietary and training patterns during the study. All blood samples were obtained at the same time of day (0700-0900) to minimize diurnal variation. Hormone concentrations were statistically analyzed by ANOVA and Tukey’s HSD post-hoc test. Dependent t-tests were used to compare changes in blood chemistries. Statistical significance was accepted at p<0.05.

Results: Compared to baseline, NOV-XT administration rapidly and significantly increased TT and BT. Mean changes from baseline for TT after one, two, three, and four weeks of NOV-XT administration were: +145% (p<0.006), +183% (p<0.0005), +232% (p<0.0002), and +240% (p<0.0002), respectively. Mean changes from baseline for BT after one, two, three, and four weeks of NOV-XT administration were: +300% (p<0.01), +402% (p<0.0009), +511% (p<0.0002), and +528% (p<0.0002), respectively. Despite these large increases in TT and BT, no significant aromatization to estradiol occurred (i.e., E2 concentrations remained unchanged). No significant changes in clinical blood chemistries (fasting glucose, BUN, creatinine, bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, sodium, potassium, chloride, calcium, albumin, globulin, CO2, total protein, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol) or systemic hemodynamics (heart rate, systolic blood pressure, diastolic blood pressure) were observed, nor were any adverse events noted during the study.

Variable Baseline Day 7 Day 14 Day 21 Day 28
Testosterone (ng/dL) 517 (162) 1265 (252) * 1515 (212) * 1714 (322) * 1758 (435) *
Bio T (ng/dL) 159 (57) 636 (265) * 798 (94) * 971 (226) * 998 (210) *
Estradiol (pg/mL) 22 (3) 19 (9) 16 (9) 19 (11) 19 (9)
Glucose (mg/dL) 90 (4) 87 (10)
BUN:Cr 17 (5) 17 (4)
Bilirubin (mg/dL) 0.8 (0.5) 0.9 (0.5)
ALP (IU/L) 84 (32) 67 (43)
AST (IU/L) 27 (7) 27 (8)
ALT (IU/L) 29 (11) 31 (15)
Chol (mg/dL) 156 (19) 163 (27)
TAG (mg/dL) 74 (22) 72 (19)
HDL (mg/dL) 54 (3) 51 (9)
LDL (mg/dL) 87 (18) 97 (20)
SBP (mm Hg) 124 (5) 124 (11)
DBP (mm Hg) 75 (6) 74 (14)